Skip to content

Marta Torrens

31 papers in the library · 1,230 citations · publishing 2004-2025

Papers

Sort Most recent Most cited

Is there a risk of esketamine misuse in clinical practice?

Therapeutic advances in drug safety 2025 Carlos Roncero, Milton Merizalde-Torres, Néstor Szerman et al. 11 citations

In 2019, intranasal esketamine gained approval as a promising therapy for those individuals grappling with treatment-resistant depression. Both clinical trials and real-world studies have underscored its efficacy in alleviating and remitting depressive symptoms, with sustained benefits observed for nearly 4.5 years. As the S-enantiomer of ketamine, esketamine's dosing guidelines and strict...

Pharmacological effects of methylone and MDMA in humans

Frontiers in Pharmacology February 17, 2023 Lourdes Poyatos, Clara Pérez‐mañá, Olga Hladun et al. 26 citations

Methylone is one of the most common synthetic cathinones popularized as a substitute for 3,4-methylenedioxymethamphetamine (MDMA, midomafetamine) owing to its similar effects among users. Both psychostimulants exhibit similar chemistry (i.e., methylone is a β-keto analog of MDMA) and mechanisms of action. Currently, the pharmacology of methylone remains scarcely explored in humans. Herein, we...

Abuse Potential of Cathinones in Humans: A Systematic Review

Journal of Clinical Medicine February 15, 2022 Lourdes Poyatos, A Acuna Torres, Esther Papaseit et al. 26 citations

Introduction and objective: Assessing the abuse potential of new substances with central nervous system activity is essential for preventing possible risks of misuse and addiction. The same methodology is recommended for the evaluation of the abuse potential of recreational drugs. This systematic review aims to assess the pharmacological effects related to the abuse potential and...

A Comparison of Acute Pharmacological Effects of Methylone and MDMA Administration in Humans and Oral Fluid Concentrations as Biomarkers of Exposure

Biology August 17, 2021 Lourdes Poyatos, Esther Papaseit, Eulàlia Olesti et al. 26 citations

Considered the β-keto analogue of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy), 3,4-Methylenedioxymethcathinone (methylone) is a synthetic cathinone. Over the years, methylone has been used as a substitute for conventional psychostimulants, such as MDMA. To date, little is known about the human pharmacology of methylone; the only available information has been provided by surveys or...

Acute Pharmacological Effects of Oral and Intranasal Mephedrone: An Observational Study in Humans

Pharmaceuticals January 28, 2021 Esther Papaseit, Eulàlia Olesti, Clara Pérez‐mañá et al. 30 citations

Mephedrone (4-methylmethcathinone) is a synthetic cathinone with psychostimulant properties which remains one of the most popular new psychoactive substances (NPS). It is frequently used orally and/or intranasally. To date, no studies have evaluated the acute effects and pharmacokinetics after self-administration of mephedrone orally (ingestion) and intranasally (insufflation) in naturalistic...

DOI: 10.3390/ph14020100 (opens in new tab) Mephedrone Cathinone Nasal administration Pharmacology +8

MDMA interactions with pharmaceuticals and drugs of abuse

Expert Opinion on Drug Metabolism & Toxicology March 31, 2020 Esther Papaseit, Clara Pérez‐mañá, Marta Torrens et al. 34 citations

Introduction: MDMA (3,4-methylenedioxymethamphetamine), a synthetic ring-substituted amphetamine, has become one of the most widely used recreational psychostimulant drugs in the world. Among recreational ecstasy/MDMA users, polydrug use is a phenomenon whose common purpose is to experience the synergistic effect of the combined drugs, moderate MDMA effects, prevent potential toxicity, enhance...

Acute Effects of 2C-E in Humans: An Observational Study

Frontiers in Pharmacology March 18, 2020 Esther Papaseit, Marta Torrens, Mireia Ventura et al. 20 citations

2,5-Dimethoxy-4-ethylphenethylamine (2C-E) is psychedelic phenylethylamine, with a chemical structure similar to mescaline, used as new psychoactive substance (NPS). It inhibits norepinephrine and serotonin uptake and, more relevant, acts as a partial agonist of the serotonin 2A (5-HT2 A), 2B (5-HT2 B), and (5-HT2 C) receptors. Consumers have reported that 2C-E induces mild-moderate psychedelic...

Mephedrone and Alcohol Interactions in Humans

Frontiers in Pharmacology January 28, 2020 Esther Papaseit, Clara Pérez‐mañá, Elizabeth B. de Sousa Fernandes Perna et al. 27 citations

Mephedrone (4-MMC, mephedrone) is a synthetic cathinone derivative included in the class of new psychoactive substances. It is commonly used simultaneously with alcohol (ethanol). The aim of the present study was to evaluate the interactions on subjective, cardiovascular and hormone effects and pharmacokinetics between mephedrone and alcohol in humans. Eleven male volunteers participated as...

DOI: 10.3389/fphar.2019.01588 (opens in new tab) Full text (opens in new tab) 4-methylmethcathinone mephedrone New psychoactive substance Alcohol ethanol Interaction +2

Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials

Frontiers in Psychiatry January 21, 2020 Juan José Fuentes, Francina Fonseca, Matilde Elices et al. 176 citations

Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a...

DOI: 10.3389/fpsyt.2019.00943 (opens in new tab) Anxiety Addiction Randomized controlled trial Clinical trial +5

Cannabinoids: from pot to lab

International Journal of Medical Sciences August 6, 2018 Esther Papaseit, Clara Pérez‐mañá, A. P. Pérez-Acevedo et al.

Cannabis is becoming increasingly present in our society. In recent years, the line between the natural (cannabis) and the synthetic (synthetic cannabinoids), the recreational (cannabis) and the medical (pharmaceutical cannabinoids and medical cannabis) has been crossed. In this paper we review some of the novel aspects of cannabis and cannabinoids in relation to their legal situation, changes...

Acute Pharmacological Effects of 2C-B in Humans: An Observational Study

Frontiers in Pharmacology March 13, 2018 Esther Papaseit, Marta Torrens, Mireia Ventura et al. 61 citations

2,5-dimethoxy-4-bromophenethylamine (2C-B) is a psychedelic phenylethylamine derivative, structurally similar to mescaline. It is a serotonin 5-hydroxytryptamine-2A (5-HT2A), 5-hydroxytryptamine-2B (5-HT2B), and 5-hydroxytryptamine-2C (5-HT2C) receptor partial agonist used recreationally as a new psychoactive substance. It has been reported that 2C-B induces mild psychedelic effects, although...

DOI: 10.3389/fphar.2018.00206 (opens in new tab) Mescaline Euphoriant Heart rate Hallucinogen +7

Key interindividual determinants in MDMA pharmacodynamics

Expert Opinion on Drug Metabolism & Toxicology January 5, 2018 Esther Papaseit, Marta Torrens, Clara Pérez‐mañá et al. 20 citations

MDMA, 3,4-methylenedioxymethamphetamine, is a synthetic phenethylamine derivative with structural and pharmacological similarities to both amphetamines and mescaline. MDMA produces characteristic amphetamine-like actions (euphoria, well-being), increases empathy, and induces pro-social effects that seem to motivate its recreational consumption and provide a basis for its potential therapeutic...

Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis

Journal of Psychoactive Drugs June 1, 2017 Álvaro José Palma-Conesa, Mireia Ventura, Liliana Galindo et al. 65 citations

New psychoactive tryptamines may be a public health risk since they intend to mimic the hallucinogenic effects of regulated psychoactive drugs. Few studies describe uses and clinical effects of unregulated new psychoactive tryptamines. This study aims (1) to explore the presence of tryptamines classified as NPS among the substances delivered for analysis to a harm-reduction organization; (2) to...

DOI: 10.1080/02791072.2017.1320732 (opens in new tab) Tryptamines Hallucinogen Pharmacology

What are sweet dreams made of? Analysis of psychoactive substances into “gummies”: A retrospective descriptive study

European Psychiatry April 1, 2017 Amira Trabsa, E. Monteagudo, D.d. Mariona et al. 2 citations

Introduction Although psychoactive substances has a long history in recreational settings, research on its composition has focused only on tablets, crystal and powder, even though new formulation for new psychoactive substances are readily available for users. Objectives To describe the presence of psychoactive substances and its characteristics in new formulations which had not previously been...

Attenuated frontal and sensory inputs to the basal ganglia in cannabis users

Addiction Biology March 3, 2016 Laura Blanco‐Hinojo, Jesus Pujol, Ben J. Harrison et al. 52 citations

Heavy cannabis use is associated with reduced motivation. The basal ganglia, central in the motivation system, have the brain's highest cannabinoid receptor density. The frontal lobe is functionally coupled to the basal ganglia via segregated frontal-subcortical circuits conveying information from internal, self-generated activity. The basal ganglia, however, receive additional influence from...

DOI: 10.1111/adb.12370 (opens in new tab) Cannabis Basal ganglia Frontal lobe Inferior frontal gyrus +6

Presence and evolution of a new psychoactive tryptamines branch

European Psychiatry March 1, 2016 Á. Palma Conesa, L. Galindo Guarín, M. Grifell Guàrdia et al.

Introduction New psychoactive substances (NPS) are substances that have recently appeared on the market and are not under international control. NPS use is experiencing an unprecedented increase. DiPT, 4-HO-DiPT and 4-AcO-DiPT are new psychoactive tryptamines and their effects may differ from those of other psychoactive tryptamines. Objective To explore the presence of DiPT, 4-HO-DiPT and...

25I-NBOMe: The legal LSD

European Psychiatry March 1, 2016 I. Ezquiaga, M. Grifell, Liliana Galindo et al.

IntroductionNovel psychoactive substances (NPS) use is progressively increasing year on year. A new group of phenethylamines sold as legal stimulants and hallucinogens is being reported increasingly since 2012. Within this group, 25I-NBOMe is an outstanding substance with powerful effects and high affinity with the serotonin 2a (5HT2a) receptor. Several toxicity cases have been reported so...

Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4 h apart Human pharmacology of MDMA after repeated doses taken 4 h apart.

European Neuropsychopharmacology October 2015 Magí Farré, Angels Tomillero, Clara Pérez‐mañá et al.

3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a popular psychostimulant, frequently associated with multiple administrations over a short period of time. Repeated administration of MDMA in experimental settings induces tolerance and metabolic inhibition. The aim is to determine the acute pharmacological effects and pharmacokinetics resulting from two consecutive 100mg doses of MDMA...

Acute Effects of the Novel Psychoactive Drug 2C-B on Emotions

BioMed Research International 2015 Débora González, Marta Torrens, Magı́ Farré 44 citations

Background . 2C-B (Nexus) is one of the most widespread novel psychoactive substances. There is limited information about its pharmacological properties, and few studies in humans concern its acute and chronic effects. 2C-B has been classified as a stimulant, hallucinogen, entactogen, and/or empathogen. Objectives . To evaluate the emotional, subjective, and cardiovascular effects of 2C-B....

Functional connectivity alterations in brain networks relevant to self-awareness in chronic cannabis users.

Journal of Psychiatric Research April 2014 Jesus Pujol, Laura Blanco‐Hinojo, Albert Batalla et al.

Recreational drugs are generally used to intentionally alter conscious experience. Long-lasting cannabis users frequently seek this effect as a means to relieve negative affect states. As with conventional anxiolytic drugs, however, changes in subjective feelings may be associated with memory impairment. We have tested whether the use of cannabis, as a psychoactive compound, is associated with...

Consumption of new psychoactive substances in a Spanish sample of research chemical users.

Human Psychopharmacology: Clinical and Experimental July 1, 2013 Débora González, Mireia Ventura, Fernando Caudevilla et al. 39 citations

To know the pattern of use of new psychoactive substances (NPSs) in a Spanish sample of research chemical (RC) users and to deepen the RC user profile and risk reduction strategies employed. This study is a cross-sectional survey by means of a specific questionnaire. Recruitment was carried out at music festivals, at non-governmental organizations (NGOs), and through announcements on an online...

DOI: 10.1002/hup.2323 (opens in new tab) Full text (opens in new tab) 2c-b Consumption patterns New psychoactive substances Research chemicals +12

Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”): The Influence of Gender and Genetics (CYP2D6, COMT, 5-HTT)

PLoS One October 24, 2012 Ricardo Pardo‐lozano, M. Farré, Samanta Yubero‐lahoz et al. 67 citations

The synthetic psychostimulant MDMA (±3,4-methylenedioxymethamphetamine, ecstasy) acts as an indirect serotonin, dopamine, and norepinephrine agonist and as a mechanism-based inhibitor of the cytochrome P-450 2D6 (CYP2D6). It has been suggested that women are more sensitive to MDMA effects than men but no clinical experimental studies have satisfactorily evaluated the factors contributing to...

Phenomenon of new drugs on the Internet: the case of ketamine derivative methoxetamine

Human Psychopharmacology: Clinical and Experimental March 1, 2012 Ornella Corazza, Fabrizio Schifano, Pierluigi Simonato et al. 157 citations

On the basis of the material available both in the scientific literature and on the web, this paper aims to provide a pharmacological, chemical and behavioural overview of the novel compound methoxetamine. This is a dissociative drug related to ketamine, with a much longer duration of action and intensity of effects. A critical discussion of the availability of information on the web of...

DOI: 10.1002/hup.1242 (opens in new tab) Phenomenon The internet Scientific literature Recreation +8

Designer Drugs on the Internet: A Phenomenon Out-of-Control? The Emergence of Hallucinogenic Drug Bromo-Dragonfly

Current reviews in clinical and experimental pharmacology May 1, 2011 Ornella Corazza, Fabrizio Schifano, Magı́ Farré et al. 98 citations

Based on the material available in both the scientific literature and on the web, the present paper provides an updated pharmacological, chemical, toxicological and behavioural overview of Bromo-Dragonfly (1-(8-bromobenzo[1,2-b;4,5-b']difuran-4-yl)-2-aminopropane; 'B-fly'). B-Fly is a powerful, long lasting, LSD-like, hallucinogenic drug, which has been associated with a number of acute...

DOI: 10.2174/157488411796151129 (opens in new tab) Phenethylamines Hallucinogen The internet Psychoactive substance +7

Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues.

Psychopharmacology April 2011 Fabrizio Schifano, Antonio Albanese, Suzanne Fergus et al.

Recently, those substances deriving from the active ingredient of the Khat plant, cathinone, have been rising in popularity. Indeed, 4-methylmethcathinone (mephedrone; 'meow meow' and others) has been seen by some as a cheaper alternative to other classified recreational drugs. We aimed here at providing a state-of-the-art review on mephedrone history and prevalence of misuse, chemistry,...